Literature DB >> 26306032

Prerequisites for Functional Interleukin 31 Signaling and Its Feedback Regulation by Suppressor of Cytokine Signaling 3 (SOCS3).

Elisabeth Maier1, Michaela Mittermeir1, Stefanie Ess1, Theresa Neuper1, Angela Schmiedlechner1, Albert Duschl1, Jutta Horejs-Hoeck2.   

Abstract

Interleukin-31 (IL-31) is a T helper type 2 cell-derived cytokine tightly associated with inflammatory skin disorders. IL-31-induced signaling is mediated by a receptor complex composed of oncostatin M receptor β and the cytokine-specific receptor subunit IL-31Rα, of which there are several isoforms. The latter can be classified as long or short isoforms with respect to their intracellular domain. At present, the signaling capabilities of the different isoforms remain inchoately understood, and potential mechanisms involved in negative regulation of IL-31Rα signaling have so far not been studied in detail. Here, we show that both the long and short isoforms of IL-31Rα are capable of inducing STAT signaling. However, the presence of a functional JAK-binding box within IL-31Rα is an essential prerequisite for functional IL-31-mediated STAT3 signaling. Moreover, both the long and short isoforms require oncostatin M receptor β for their activity. We also show that IL-31 induces expression of four suppressor of cytokine signaling family members and provide evidence that SOCS3 acts as a potent feedback inhibitor of IL-31-induced signaling. Taken together, this study identifies crucial requirements for IL-31 signaling and shows its counter-regulation by SOCS3.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  IL-31 signaling; IL-31R α isoforms; OSMR β; STAT3; feedback inhibition; interleukin; receptor; signal transduction; suppressor of cytokine signaling 3 (SOCS3); suppressors of cytokine signaling 1 (SOCS1)

Mesh:

Substances:

Year:  2015        PMID: 26306032      PMCID: PMC4598987          DOI: 10.1074/jbc.M115.661306

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Structure and function of a new STAT-induced STAT inhibitor.

Authors:  T Naka; M Narazaki; M Hirata; T Matsumoto; S Minamoto; A Aono; N Nishimoto; T Kajita; T Taga; K Yoshizaki; S Akira; T Kishimoto
Journal:  Nature       Date:  1997-06-26       Impact factor: 49.962

2.  A family of cytokine-inducible inhibitors of signalling.

Authors:  R Starr; T A Willson; E M Viney; L J Murray; J R Rayner; B J Jenkins; T J Gonda; W S Alexander; D Metcalf; N A Nicola; D J Hilton
Journal:  Nature       Date:  1997-06-26       Impact factor: 49.962

3.  MCP-1 as an effector of IL-31 signaling in familial primary cutaneous amyloidosis.

Authors:  Yu-Ming Shiao; Hsiang-Ju Chung; Chih-Chiang Chen; Keng-Nan Chiang; Yun-Ting Chang; Ding-Dar Lee; Ming-Wei Lin; Shih-Feng Tsai; Isao Matsuura
Journal:  J Invest Dermatol       Date:  2013-01-10       Impact factor: 8.551

Review 4.  Gp130 and the interleukin-6 family of cytokines.

Authors:  T Taga; T Kishimoto
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

Review 5.  Dimerization of cell surface receptors in signal transduction.

Authors:  C H Heldin
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

6.  Therapeutic hope for psoriasis offered by SOCS (suppressor of cytokine signaling) mimetic peptide.

Authors:  Masato Kubo
Journal:  Eur J Immunol       Date:  2013-07       Impact factor: 5.532

7.  Reconstruction of an active SOCS3-based E3 ubiquitin ligase complex in vitro: identification of the active components and JAK2 and gp130 as substrates.

Authors:  Nadia J Kershaw; Artem Laktyushin; Nicos A Nicola; Jeffrey J Babon
Journal:  Growth Factors       Date:  2014-01-20       Impact factor: 2.511

8.  The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation.

Authors:  Xuexian O Yang; Huiyuan Zhang; Byung-Seok Kim; Xiaoyin Niu; Juan Peng; Yuhong Chen; Romica Kerketta; Young-Hee Lee; Seon Hee Chang; David B Corry; Demin Wang; Stephanie S Watowich; Chen Dong
Journal:  Nat Immunol       Date:  2013-06-02       Impact factor: 25.606

9.  IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase.

Authors:  M Murakami; M Hibi; N Nakagawa; T Nakagawa; K Yasukawa; K Yamanishi; T Taga; T Kishimoto
Journal:  Science       Date:  1993-06-18       Impact factor: 47.728

10.  Residual endotoxin contaminations in recombinant proteins are sufficient to activate human CD1c+ dendritic cells.

Authors:  Harald Schwarz; Maria Schmittner; Albert Duschl; Jutta Horejs-Hoeck
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

View more
  8 in total

Review 1.  IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Micah Belzberg; Madan M Kwatra; Shawn G Kwatra
Journal:  Drugs       Date:  2021-04-21       Impact factor: 9.546

Review 2.  Balancing STAT Activity as a Therapeutic Strategy.

Authors:  Kelsey L Polak; Noah M Chernosky; Jacob M Smigiel; Ilaria Tamagno; Mark W Jackson
Journal:  Cancers (Basel)       Date:  2019-11-03       Impact factor: 6.575

Review 3.  Interleukin-31 Signaling Bridges the Gap Between Immune Cells, the Nervous System and Epithelial Tissues.

Authors:  Jana Maria Nemmer; Marcus Kuchner; Angeliki Datsi; Péter Oláh; Valérie Julia; Ulrike Raap; Bernhard Homey
Journal:  Front Med (Lausanne)       Date:  2021-02-10

Review 4.  Interleukin-31 and Pruritic Skin.

Authors:  Masutaka Furue; Mihoko Furue
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

Review 5.  IL-31, itch and hematological malignancies.

Authors:  Eleonora Di Salvo; Alessandro Allegra; Marco Casciaro; Sebastiano Gangemi
Journal:  Clin Mol Allergy       Date:  2021-06-12

6.  Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716.

Authors:  Carl D Richards; Rohan Gandhi; Fernando Botelho; Lilian Ho; John F Paolini
Journal:  Acta Derm Venereol       Date:  2020-07-02       Impact factor: 3.875

Review 7.  IL-33/IL-31 Axis: A Potential Inflammatory Pathway.

Authors:  Eleonora Di Salvo; Elvira Ventura-Spagnolo; Marco Casciaro; Michele Navarra; Sebastiano Gangemi
Journal:  Mediators Inflamm       Date:  2018-03-11       Impact factor: 4.711

8.  Interleukin-6 Induces Myogenic Differentiation via JAK2-STAT3 Signaling in Mouse C2C12 Myoblast Cell Line and Primary Human Myoblasts.

Authors:  Paul J Steyn; Kevin Dzobo; Robert I Smith; Kathryn H Myburgh
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.